JP2021535119A5 - - Google Patents
Info
- Publication number
- JP2021535119A5 JP2021535119A5 JP2021509906A JP2021509906A JP2021535119A5 JP 2021535119 A5 JP2021535119 A5 JP 2021535119A5 JP 2021509906 A JP2021509906 A JP 2021509906A JP 2021509906 A JP2021509906 A JP 2021509906A JP 2021535119 A5 JP2021535119 A5 JP 2021535119A5
- Authority
- JP
- Japan
- Prior art keywords
- calcitonin mimetic
- amino acid
- mimetic according
- linking group
- calcitonin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024193478A JP2025023996A (ja) | 2018-08-22 | 2024-11-05 | アシル化カルシトニン模倣体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1813678.8 | 2018-08-22 | ||
| GBGB1813678.8A GB201813678D0 (en) | 2018-08-22 | 2018-08-22 | Acylated calcitonin mimetics |
| PCT/EP2019/072533 WO2020039051A1 (en) | 2018-08-22 | 2019-08-22 | Acylated calcitonin mimetics |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024193478A Division JP2025023996A (ja) | 2018-08-22 | 2024-11-05 | アシル化カルシトニン模倣体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021535119A JP2021535119A (ja) | 2021-12-16 |
| JP2021535119A5 true JP2021535119A5 (enExample) | 2024-03-13 |
Family
ID=63668212
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021509906A Pending JP2021535119A (ja) | 2018-08-22 | 2019-08-22 | アシル化カルシトニン模倣体 |
| JP2024193478A Pending JP2025023996A (ja) | 2018-08-22 | 2024-11-05 | アシル化カルシトニン模倣体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024193478A Pending JP2025023996A (ja) | 2018-08-22 | 2024-11-05 | アシル化カルシトニン模倣体 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20220380432A1 (enExample) |
| EP (1) | EP3840774A1 (enExample) |
| JP (2) | JP2021535119A (enExample) |
| KR (2) | KR102866729B1 (enExample) |
| CN (3) | CN112601542A (enExample) |
| AU (2) | AU2019323697B2 (enExample) |
| BR (1) | BR112021003088A2 (enExample) |
| CA (1) | CA3110033A1 (enExample) |
| CL (1) | CL2021000427A1 (enExample) |
| CO (1) | CO2021002071A2 (enExample) |
| EA (1) | EA202190477A1 (enExample) |
| GB (1) | GB201813678D0 (enExample) |
| IL (1) | IL280885B2 (enExample) |
| MX (1) | MX2021002072A (enExample) |
| PE (1) | PE20211785A1 (enExample) |
| PH (1) | PH12021550331A1 (enExample) |
| WO (1) | WO2020039051A1 (enExample) |
| ZA (1) | ZA202100869B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI877770B (zh) | 2018-02-27 | 2025-03-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之咪唑并嘧啶及三唑并嘧啶 |
| EP3810610A1 (en) | 2018-05-18 | 2021-04-28 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
| WO2020010197A1 (en) | 2018-07-05 | 2020-01-09 | Incyte Corporation | Fused pyrazine derivatives as a2a / a2b inhibitors |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| AR124295A1 (es) * | 2020-12-18 | 2023-03-15 | Lilly Co Eli | Agonistas duales del receptor de amilina y calcitonina y usos de los mismos |
| CA3204051A1 (en) | 2021-01-20 | 2022-07-28 | Brian Lian | Compositions and methods for the treatment of metabolic and liver disorders |
| JP7642830B2 (ja) | 2021-09-15 | 2025-03-10 | バイキング・セラピューティクス・インコーポレイテッド | 代謝及び肝臓障害の処置のための組成物及び方法 |
| CN118684757A (zh) * | 2023-03-24 | 2024-09-24 | 成都奥达生物科技有限公司 | 一种长效降钙素类似物 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6319685B1 (en) | 1984-09-27 | 2001-11-20 | Unigene Laboratories, Inc. | Alpha-amidating enzyme compositions and processes for their production and use |
| US4708934A (en) | 1984-09-27 | 1987-11-24 | Unigene Laboratories, Inc. | α-amidation enzyme |
| US5789234A (en) | 1987-08-14 | 1998-08-04 | Unigene Laboratories, Inc. | Expression systems for amidating enzyme |
| US5102666A (en) | 1990-09-11 | 1992-04-07 | Oramed, Inc. | Calcium polycarbophil controlled release composition and method |
| US5359030A (en) | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| US6692766B1 (en) | 1994-06-15 | 2004-02-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Controlled release oral drug delivery system |
| US5866536A (en) | 1995-03-31 | 1999-02-02 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US5912014A (en) | 1996-03-15 | 1999-06-15 | Unigene Laboratories, Inc. | Oral salmon calcitonin pharmaceutical products |
| US5773647A (en) | 1997-02-07 | 1998-06-30 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| WO1998046722A1 (en) | 1997-04-16 | 1998-10-22 | Unigene Laboratories Inc. | Direct expression of peptides into culture media |
| JP2002531518A (ja) | 1998-12-04 | 2002-09-24 | プロヴァリス・ユーケー・リミテッド | インスリン含有医薬組成物 |
| ES2235854T3 (es) | 1999-04-05 | 2005-07-16 | Emisphere Technologies, Inc. | Sales disodicas, monohidratos y solvatos etanolicos para aportar agentes activos. |
| US6780846B1 (en) | 1999-09-27 | 2004-08-24 | Elan Corporation, Plc | Membrane translocating peptide drug delivery system |
| GB2368792A (en) | 2000-10-06 | 2002-05-15 | Roger Randal Charles New | Absorption enhancers |
| US6673574B2 (en) | 2000-11-30 | 2004-01-06 | Unigene Laboratories Inc. | Oral delivery of peptides using enzyme-cleavable membrane translocators |
| US7316819B2 (en) | 2001-03-08 | 2008-01-08 | Unigene Laboratories, Inc. | Oral peptide pharmaceutical dosage form and method of production |
| US6713452B2 (en) * | 2001-06-04 | 2004-03-30 | Nobex Corporation | Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| WO2005004792A2 (en) * | 2003-06-24 | 2005-01-20 | Nobex Corporation | Mixtures of calcitonin drug-oligomer conjugates and methods of use in pain treatment |
| US6770625B2 (en) | 2001-09-07 | 2004-08-03 | Nobex Corporation | Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith |
| ES2665464T3 (es) | 2003-03-28 | 2018-04-25 | Sigmoid Pharma Limited | Forma de dosificación oral sólida que contiene microcápsulas sin costuras |
| GB0308732D0 (en) | 2003-04-15 | 2003-05-21 | Axcess Ltd | Absorption enhancers |
| ES2398237T3 (es) | 2003-07-23 | 2013-03-14 | Novartis Ag | Uso de calcitonina en osteoartritis |
| US20070172517A1 (en) | 2003-09-17 | 2007-07-26 | Ben-Sasson Shmuel A | Compositions capable of facilitation penetration across a biological barrier |
| AU2005263729B2 (en) | 2004-07-22 | 2011-01-06 | Bey Pharma GmbH | Use of compounds containing thiol groups as an efflux pump inhibitor |
| US7445911B2 (en) | 2004-11-24 | 2008-11-04 | Unigene Laboratories Inc. | Enzymatic reactions in the presence of keto acids |
| AU2006261909B2 (en) | 2005-06-24 | 2011-08-11 | Enteris Biopharma, Inc. | Cell lines for expressing enzyme useful in the preparation of amidated products |
| WO2007029238A2 (en) | 2005-09-06 | 2007-03-15 | Oramed Pharmaceuticals, Inc. | Methods and compositions for oral administration of proteins |
| US8093207B2 (en) | 2005-12-09 | 2012-01-10 | Unigene Laboratories, Inc. | Fast-acting oral peptide pharmaceutical products |
| EP1834635B1 (en) | 2006-03-13 | 2011-07-06 | Advanced in Vitro Cell Technologies, S.L. | Stable nanocapsule systems for the administration of active molecules |
| BRPI0710503A2 (pt) | 2006-04-07 | 2011-08-16 | Merrion Res Iii Ltd | uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral |
| US8377863B2 (en) | 2007-05-29 | 2013-02-19 | Unigene Laboratories Inc. | Peptide pharmaceutical for oral delivery |
| US8962015B2 (en) | 2007-09-28 | 2015-02-24 | Sdg, Inc. | Orally bioavailable lipid-based constructs |
| CA2755068C (en) * | 2009-03-12 | 2018-11-06 | Keybioscience Ag | Treatment of diabetes and metabolic syndrome |
| EP2493919A1 (en) * | 2009-10-30 | 2012-09-05 | Novo Nordisk A/S | Derivatives of cgrp |
| JP6039569B2 (ja) * | 2010-11-09 | 2016-12-07 | ノヴォ ノルディスク アー／エス | 二重アシル化されたｇｌｐ−１誘導体 |
| US9533022B2 (en) * | 2011-11-02 | 2017-01-03 | KeyBioscience A/S | Peptide analogs for treating diseases and disorders |
| EP3357540A1 (en) * | 2011-11-02 | 2018-08-08 | KeyBioscience AG | Combination of calcitonin mimetic and insulin sensitizer |
| US9006172B2 (en) * | 2011-11-02 | 2015-04-14 | Keybioscience Ag | Peptide analogs for treating diseases and disorders |
| CN105722854B (zh) | 2013-11-14 | 2020-08-04 | 关键生物科学有限公司 | 用于治疗疾病和病症的降钙素模拟物 |
| GB201500263D0 (en) * | 2015-01-08 | 2015-02-25 | Keybioscience Ag | Calcitonin analogues for treating diseases and disorders |
| JP2018529749A (ja) * | 2015-10-07 | 2018-10-11 | シプルメット・ゲーエムベーハー | ペプチド薬物を経口送達するための医薬製剤 |
| JP2019517523A (ja) * | 2016-06-03 | 2019-06-24 | ケモセントリックス， インコーポレイテッド | 肝線維症を治療する方法 |
-
2018
- 2018-08-22 GB GBGB1813678.8A patent/GB201813678D0/en not_active Ceased
-
2019
- 2019-08-22 IL IL280885A patent/IL280885B2/en unknown
- 2019-08-22 KR KR1020217008022A patent/KR102866729B1/ko active Active
- 2019-08-22 KR KR1020257032307A patent/KR20250143876A/ko active Pending
- 2019-08-22 AU AU2019323697A patent/AU2019323697B2/en active Active
- 2019-08-22 WO PCT/EP2019/072533 patent/WO2020039051A1/en not_active Ceased
- 2019-08-22 MX MX2021002072A patent/MX2021002072A/es unknown
- 2019-08-22 US US17/270,331 patent/US20220380432A1/en active Pending
- 2019-08-22 JP JP2021509906A patent/JP2021535119A/ja active Pending
- 2019-08-22 CN CN201980055426.8A patent/CN112601542A/zh active Pending
- 2019-08-22 PE PE2021000229A patent/PE20211785A1/es unknown
- 2019-08-22 BR BR112021003088-3A patent/BR112021003088A2/pt unknown
- 2019-08-22 EP EP19765419.7A patent/EP3840774A1/en active Pending
- 2019-08-22 CN CN202511289422.XA patent/CN121021664A/zh active Pending
- 2019-08-22 EA EA202190477A patent/EA202190477A1/ru unknown
- 2019-08-22 CN CN202511289522.2A patent/CN121226531A/zh active Pending
- 2019-08-22 CA CA3110033A patent/CA3110033A1/en active Pending
-
2021
- 2021-02-09 ZA ZA2021/00869A patent/ZA202100869B/en unknown
- 2021-02-16 PH PH12021550331A patent/PH12021550331A1/en unknown
- 2021-02-19 CL CL2021000427A patent/CL2021000427A1/es unknown
- 2021-02-22 CO CONC2021/0002071A patent/CO2021002071A2/es unknown
-
2024
- 2024-11-05 JP JP2024193478A patent/JP2025023996A/ja active Pending
-
2025
- 2025-07-04 AU AU2025205152A patent/AU2025205152A1/en active Pending